3:28 PM
 | 
Dec 04, 2017
 |  BC Extra  |  Company News

Mustang, Harvard partner on CRISPR CAR T therapies

Mustang Bio Inc. (NASDAQ:MBIO) partnered with Harvard University to develop CRISPR-Cas9-enhanced CAR T therapies targeting hematologic and solid tumor cancers.

The biotech in-licensed CRISPR-Cas9 gene editing technology from Harvard, as well as technology related to the development of off-the-shelf CAR T cells, for use in conjunction with Mustang's CAR T cell therapies.

The technologies were developed by Chad Cowan, a pioneer of CRISPR-Cas9 technology. Cowen is an associate professor of...

Read the full 331 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >